NIHR reveals phase 1/2 trial to evaluate an investigational vaccine for mpox in the UK
More than 3,700 cases of mpox have been identified in the UK since May 2022
Read More
Tag: Moderna-UK
First UK patients receive experimental mRNA therapy for cancer in global trial
The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359
Read More
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
